Company intelligence / Profile preview

Tiberias Technology

Hong Kong, China (Hong Kong SAR)

Ownership: Private
Development stage: Other

Overview

TibTech is developing and commercializing advanced diagnostic assays (LDTs, IVDs) for gastrointestinal cancers, leveraging clinical samples and the parent company's (Arbele) lead immunotherapy candidate ARB202. The focus is on companion diagnostics to guide patient selection for novel T-cell engager immunotherapies

Therapeutic areas: Oncology
Modalities: In vitro diagnostics (IVD)Laboratory developed tests (LDTs)
Industry: Molecular Diagnostics

Partnerships

Cooperation with clinical sites in Hong Kong, China (Guangzhou), likely clinical trial partners tied to Arbele

Beyond the preview

Go deeper on Tiberias Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tiberias Technology.

Explore the full profile